Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833136 | 0.73 | — | — | |
| SCHEMBL8607450 | 0.69 | — | — | |
| SCHEMBL19913407 | 0.68 | TOP2A (0.33) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL20976341 | 0.68 | TOP2A (0.47) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL13625472 | 0.66 | TOP2A (0.42) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL19113417 | 0.65 | — | — | |
| SCHEMBL2625759 | 0.65 | MEN1 (0.39) | SMN1; SMN2 | |
| SCHEMBL23922208 | 0.64 | CRHBP (0.36) | ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL13857354 | 0.64 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL7395327 | 0.62 | SMN1; SMN2 (0.41) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11148998-B2 | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11148998-B2 | Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof | RARB, RXRB, RXRA | TOP2A 2237/4885TOP2B 2287/4885ALDH1A1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.